12/15/2016 - 3:51pm

At CVS Health’s annual analyst day presentations in New York, the company’s leadership touted the areas in which it excels and its ability to ‘own the last mile of care.’

12/07/2016 - 11:45am

In an interview with Time published Tuesday morning to accompany his being chosen as the magazine’s “Person of the Year,” President-elect Donald Trump told the magazine that one of his goals as president is lowering the cost of prescription drugs.  

12/06/2016 - 6:02pm

As consumer dietary habits have shifted in recent years, confectionary companies have had a tougher task of finding ways to drive growth in the candy aisles.

12/01/2016 - 11:04am

For the fourth quarter of 2016, Kroger expects slightly positive identical supermarket sales growth, excluding fuel.

11/17/2016 - 9:29am

Walmart noted that e-commerce has contributed 50 basis points to its comparable growth of 1.2%, which is the strongest contribution, yet.

11/16/2016 - 4:02pm

Beer is still America’s No. 1 alcoholic beverage, but retail experts say that U.S. consumers are buying less of it as they turn to other alcohol types, such as hard soda, cider and wine.

11/16/2016 - 4:02pm

U.S. consumers are increasingly prioritizing health and wellness in their decision-making, and this is especially true when it comes to beverages.

11/16/2016 - 10:08am

Same-store sales across Shoppers Drug Mart outlets were up 2.8%, with same-store pharmacy sales increasing by 1.6% and same-store front store sales increasing by 3.9%.

11/09/2016 - 1:22pm
Business Insider is reporting that as news that Donald Trump will be the 45th president sent stocks into an early Thursday tumble in Europe, by around 9:50 a.m. in London (4:50 a.m. EST), pharmaceutical stocks were rising, with Hikma Pharmaceuticals’s stock up 6% on the FTSE 100. Roche and Novartis saw stock increases over 4% and GSK saw a 1.8% bump. Jefferies pointed to hope that efforts to enact new pricing rules on drugs led the swell, telling Business Insider, “Sentiment towards the Healthcare sector ought to swing initially away from draconian fears over drug pricing.” (Business Insider)